Full Press Release Details
IDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline.
IDYA
IDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline
Key Takeaway: IDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline